MedTrace Logo

Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses

NCT01703026 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2012-10-10

No results posted yet for this study

Summary

Contrast enhanced EUS with the sonographic contrast agent DEFINITY™ has the potential to detect pancreatic cancer at an earlier stage, to improve current method of T staging and assessment of surgical resectability and also to distinguish between benign and malignant pancreatic masses. All these will translate into better clinical outcome, and also avoid unnecessary surgery in situations of unresectable cancers.

Conditions

Sponsors & Collaborators

  • Changi General Hospital

    lead OTHER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Completion
2011-10-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01703026 on ClinicalTrials.gov